Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022

- Phase 2 data demonstrate that the addition of parsaclisib to ruxolitinib (Jakafi®) resulted in spleen volume reduction and improvement in symptom burden in patients with myelofibrosis (MF)

- Initial results of a Phase 1/2 study evaluating the safety and tolerability of INCB00928, an ALK2 inhibitor, show INCB00928 improves anemia in patients with MF both as monotherapy and in combination with ruxolitinib

- These studies are part of our LIMBER program evaluating ruxolitinib combinations and potential new targets for appropriate patients with myeloproliferative neoplasms (MPNs)

Related Keywords

Delaware ,United States ,American ,Mascarenhasj Hemasphere ,Peter Langmuir ,Abdulraheem Yacoub ,Drug Administration ,American Society Of Hematology ,Exchange Commission ,Landmark Survey Available ,University Of Kansas Cancer Center ,Oncology Drug Development Incyte ,Research Foundation ,Incyte Corporation ,These Phase ,American Society ,Annual Meeting ,New Orleans ,Vice President ,Oncology Drug Development ,Associate Professor ,Hematologic Malignancies ,Cellular Therapeutics ,Kansas Cancer ,Full Prescribing Information ,Incyte Medical Information ,Add On Parsaclisib ,Ruxolitinib Therapy ,Myelofibrosis Patients With Suboptimal Response ,Final Results From ,Anemia Due ,Accessed February ,